Clinical Trial Update: GV1001 and Gemcitabine in Sequential Combination to Gemcitabine Monotherapy in Pancreatic Cancer [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating sequential GV1001 plus gemcitabine followed by gemcitabine monotherapy for advanced unresectable pancreatic cancer was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• GV1001
• Gemcitabine (Gemcitabine)

Snippet

Sponsor: Pharmexa A/S | Conditions: Advanced Unresectable Pancreatic Cancer | Phase 3 | Status: TERMINATED